Oncoceutics Inc.
Back on the cancer TRAIL
This article was originally published in Start Up
Executive Summary
Tumor necrosis factor-related apoptosis-inducing ligand has been a tantalizing cancer target since it was first cloned and characterized 20 years ago, but the performance of TRAIL agonists in the clinic over the past decade, all of them antibodies, has been disappointing. Now Oncoceutics Inc. may be on the verge of reviving the promise of TRAIL with a small molecule that works by triggering a cascade of tumor suppressing pathways.